Loading patent…
OwnerMasanobu Kobayashiinventor
Estimating the term…
Pharmaceutical compositions containing adrenomedullin antagonist peptides, DNA, RNA compounds inhibitory on adrenomedullin activity, resulting in the efficient blockade of the induction of macroangiogenesis or vasculogenesis of more than 8 μm (in case of murine models), suppress the proliferation of cancer cells due to that inhibitory effect and suppress the protective activity of adrenomedullin. Accordingly, the pharmaceutical compositions of the present invention described herein can be used to treat various cancers, including, but not limited to, stomach cancer, colorectal cancer, lung cancer, ovarian cancer, liver cancer, and pancreatic cancer. Pharmaceutical compositions containing adrenomedullin expression vectors described herein induce macroangiogenesis and, accordingly are effective in treating cardiovascular and renal diseases such as congestive heart failure, myocardial infarction, hypertension, chronic renal failure, stroke, diabetes mellitus, and septic shock.
1-33. (canceled)
An isolated nucleic acid encoding a truncated peptide, wherein said truncated peptide comprises the amino acid sequence set forth in SEQ ID NO:1 in which at least one but no more than twenty-five amino acids are deleted from the N-terminal side, wherein said truncated peptide inhibits the finction of adrenomedullin to generate macroangiogenesis.
A pharmaceutical composition for inhibiting tumor angiogenesis comprising a compound capable of inhibiting the finction of adrenomedullin to generate macroangiogenesis.
A method for treating cardiovascular and renal disease, comprising administering a peptide having the sequence shown in SEQ ID NO:1, wherein said peptide induces or generates macroangiogenesis.
Dependencies are inferred from the claim text.